LeonaBio

LeonaBio EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of LeonaBio (LONA) as of Oct 16, 2026 is -110.98 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -171.66 % — a change of -35.35% (higher).

EBIT/Assets

-110.98 %

YoY

-35.35%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of LeonaBio is 2025 -110.98 % . Operating Income to Assets Ratio (EBIT/Assets) of LeonaBio was 2024 -171.66 % . It decreases by -35.35% higher compared to the previous year.

The LeonaBio EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-101.54 USD
Jan 1, 2019
-248.93 USD
Jan 1, 2020
-7.15 USD
Jan 1, 2021
-19.28 USD
Jan 1, 2022
-40.29 USD
Jan 1, 2023
-78.30 USD
Jan 1, 2024
-171.66 USD
Jan 1, 2025
-110.98 USD
The LeonaBio EBIT/Assets history
YEAREBIT/AssetsYoY
-110.98 %-35.35%
-171.66 %+119.25%
-78.30 %+94.32%
-40.29 %+108.95%
-19.28 %+169.61%
-7.15 %-97.13%
-248.93 %+145.15%
-101.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LeonaBio Stock analysis

What does LeonaBio do? LeonaBio Inc, trading under the ticker LONA with ISIN US04746L2034, is a U.S.-based company headquartered in Bothell, Washington. Operating within the Health Care sector, specifically in the Pharmaceuticals industry, the company has a workforce of 20 employees. LeonaBio Inc. completed its initial public offering (IPO) on September 18, 2020. The company's website is https://www.athira.com/. It is important to note that the provided source description refers to Athira Pharma, Inc., which appears to be a different entity from LeonaBio Inc. The source description mentions a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, with a pipeline built from an ATH platform. However, these details are not confirmed as part of LeonaBio Inc. and should not be attributed to it. The company's actual business focus, product pipeline, or technological platforms are not specified in the provided information. LeonaBio Inc. is a publicly traded company with a small team, operating in the pharmaceutical space, but specific details about its products, research, or development activities are not included in the facts provided. LeonaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LeonaBio stock

Operating Income to Assets Ratio (EBIT/Assets) of LeonaBio is -110.98 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of LeonaBio changed from -171.66 % to -110.98 %, representing a -35.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) LeonaBio since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s LeonaBio with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — LeonaBio

All Key Metrics — LeonaBio